Patients with paroxysmal atrial fibrillation but not paroxysmal supraventricular tachycardia display evidence of platelet activation during arrhythmia

Platelets

Volumn 14, Issue 7-8, 2003, Pages 407-411

  Atalar, Enver ^a,b   Haznedaroglu, Ibrahim C ^a   Acil, Tayfun ^a   Ozer, Necla ^a   Kilic, Harun ^a   Ovunc, Kenan ^a   Aksoyek, Serdar ^a   Nazli, Nasih ^a   Kes, Sirri ^a   Kabakçi, Giray ^a   Kirazli, Serafettin ^a   Ozmen, Ferhan ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

^b Konutkent II   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

BETA THROMBOGLOBULIN; THROMBOCYTE FACTOR 4;

ADULT; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CARDIOVERSION; CELL ACTIVITY; CHRONIC DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEMOSTASIS; HUMAN; HUMAN CELL; MALE; MEASUREMENT; PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA; PRIORITY JOURNAL; PROTEIN DETERMINATION; SINUS RHYTHM; THROMBOCYTE ACTIVATION;

ADULT; ARRHYTHMIA; ATRIAL FIBRILLATION; BETA-THROMBOGLOBULIN; BLOOD PLATELETS; ELECTRIC COUNTERSHOCK; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET ACTIVATION; PLATELET FACTOR 4; TACHYCARDIA, PAROXYSMAL; TACHYCARDIA, SUPRAVENTRICULAR;

EID: 0347302938     PISSN: 09537104     EISSN: None     Source Type: Journal    
DOI: 10.1080/09537100310001638814     Document Type: Article

References (24)

1. Wolf P A, Abbot R D, Kannel W B. Atrial fibrillation: as an independent risk factor for stroke: The Framingham Study. Stroke 1991; 22: 983-88.
2. Feng D, D'Agostino B R, Silberschatz H, Lipinska I, Massaro J, Levy D, et al. Hemostatic state and atrial fibrillation (The Framingham Offspring Study). Am J Cardiol 2001; 87: 168-171.
3. Takahashi N, Seki A, Imataka K, Fujii J. Clinical features of paroxysmal atrial fibrillation: an observation of 94 patients. Jpn Circ J 1981; 22: 143-9.
4. Petersen P, Godtfredsen J. Embolic complication in paroxysmal atrial fibrillation. Stroke 1986; 17: 622-6.
5. Yamaguchi K, Furui H, Taniguchi N, Sotobata I. Plasma β-thromboglobulin and platelet factor 4 concentrations in patients with atrial fibrillation. Jpn Heart J 1986; 27: 481-7.
6. Gustafsson C, Blomback M, Britton M, Hamsten A, Svensson J. Coagulation factors and the risk of stroke in non-valvular atrial fibrillation. Stroke 1990; 21: 47-51.
7. Kumagai K, Fukunami M, Ohmori M, Kitabatake A, Kamada T, Hori N. Increased intra-cardiovascular clotting in patients with chronic atrial fibrillation. J Am Coll Cardiol 1990; 16: 377-80.
8. Sohara H, Miyahara K. Effect of atrial fibrillation on the fibrinocoagulation system: in patients with paroxysmal atrial fibrillation. Jpn Circ J 1994; 58: 821-26.
9. Lip G Y H, Lip P L, Zarifis J, Watson R D, Bareford D, Lowe G D, Beevers D G. Fibrin D-dimer and b-thromboglobulin as markers of thrombogenesis and platelet activation in atrial fibrillation. Circulation 1996; 94: 425-31.
10. Sohara H, Amitani S, Kurose M, Miyahara K. Atrial fibrillation activates platelets and coagulation in a time-dependent manner: A study in patients with paroxysmal atrial fibrillation. J Am Coll Cardiol 1997; 29: 106-12.
11. Roldan V, Marin F, Marco P, Martinez J G, Calatayud C, Sogorb F. Hypofibrinolysis in atrial fibrillation. Am Heart J 1998; 136: 956-60.
12. Li-Saw-Hee F L, Blann A D, Lip G Y H. Plasma von Willebrand factor, fibrinogen and soluble P-selectin levels in paroxysmal, persistent and permanent atrial fibrillation. Eur Heart J 2001; 22: 1741-47.
13. Atalar E, Ozmen F, Haznedaroglu I, Ozer N, Aksoyek S, Ovunc K, et al. Impaired fibrinolytic capacity in rheumatic mitral stenosis with or without atrial fibrillation and nonrheumatic atraial fibrillation. Int J Hematology 2002; 76: 192-95.
14. Sopher S M, Camm A J. Atrial fibrillation - maintenance of sinus rhythm versus rate control. Am J Cardiol 1996; 77: 24A-38A.
15. Lip G Y H, Rumley A, Dunn F G. Plasma fibrinogen and fibrin D-dimer levels in paroxysmal atrial fibrillation: Evidence of intermediate levels of intravascular thrombogenesis. Am Heart J 1996; 131: 724-30.
16. Lip G Y H. Does paroxysmal atrial fibrillation confer a paroxysmal thromboembolic risk? Lancet 1977; 349: 1565-66.
17. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized trials. Arch Intern Med 1994; 154: 1449-57.
18. Atluru V L, Epstein L G, Gootman N. Childhood stroke and supraventricular tachycardia. Pediatr Neurol 1985; 1: 54-6.
19. Aronow W S, Ahn C, Mercando A D, Epstein S, Gutstein H. Correlation of paroxysmal supraventricular tachycardia, atrial fibrillation, and sinus rhythm with incidences of new thromboembolic stroke in 1476 old-old patients. Aging 1996; 8: 32-4.
20. Baumgartner H R. The role of blood flow in platelet adhesion, fibrin deposition and formation of mural thrombi. Microvasc Res 1973; 5: 167-79.
21. Turitto V T, Weiss H J. Red blood cells: their role in thrombosis formation. Science 1980; 207: 541-43.
22. Shapiro E P, Effron M B, Lima S, Ouyang P, Siu CO, Bush D. Transient atrial dysfunction after cardioversion of chronic atrial fibrillation to sinus rhythm. Am J Cardiol 1988; 62: 1202-07.
23. Nishino M, Hoshida S, Tanouchi J, Ito T, Kato J, Iwai K, et al. Time to recover from atrial hormonal, mechanical, and electrical dysfunction after successful electrical cardioversion of persistent atrial fibrillation. Am J Cardiol 2000; 85: 1451-54.
24. Wozakosa-Kaplon B, Opolski G. Concominant recovery of atrial mechanical and endocrine function after cardioversion in patients with persistent atrial fibrillation. J Am Coll Cardiol 2003; 41: 1716-20.